60 Degrees Pharmaceuticals, Inc.

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.04, indicating minimal leverage relative to its equity base of $3.46 million. Total liabilities stand at $1.99 million against total assets of $5.37 million. Liquidity is supported by cash and equivalents of $1.51 million, which covers the long-term debt of $144,003. However, the risk assessment flags liquidity as low, likely due to the significant cash burn from operations.

Profitability metrics are deeply negative, reflecting the early-stage or development phase of the business. Return on equity is -2.13 and return on assets is -1.37, driven by an operating income loss of $7.76 million and a net income loss of $7.37 million. The gross profit of $223,776 on revenue of $1.01 million suggests a gross margin of approximately 22%, but this is insufficient to cover operating expenses.

Revenue concentration data is not provided in the available segments or geography sections, preventing a detailed analysis of product or regional mix. The total revenue of $1.01 million indicates a small scale of commercial operations.

Growth trajectory cannot be assessed due to the absence of historical period data for revenue or net income trends. The current financial snapshot represents a single point in time without comparative historical context to determine acceleration or deceleration.

Risk factors include low liquidity and low dilution risk. The key flags indicate no immediate filing-based liquidity or dilution issues, but the negative operating cash flow of $6.85 million poses a fundamental sustainability challenge. The company must rely on its existing cash reserves or external financing to continue operations.

Recent news observations are limited to internal system reconciler events regarding analysis job queuing, with no substantive business news, filing observations, or transcript insights available to inform the current outlook.